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Abstract
Background: Pregnancies induced  by in vitro fertilisation (IVF) often result in twin gestations, which are associated 
with bo th  maternal and perinatal complications. An effective way to  reduce  th e  n u m b e r  of IVF twin pregnanc ies  is 
to  decrease  th e  n u m b e r  of em bryos  transferred from tw o  to  one. The interpretation of current studies is limited 
because  th ey  used live birth as o u tc o m e  m easure  and  because  th ey  applied limited tim e horizons. So far, research 
on long-term o u tc o m e s  of IVF twins and singletons is scarce and  inconclusive. The objective of this s tudy is to 
investigate th e  short (1-year) and  long-term (5 and 18-year) costs and  health o u tco m es  of IVF singleton and  twin 
children and  to  consider these  in estimating th e  cost-effectiveness of single em bryo  transfer co m p ared  with 
d o ub le  em bryo  transfer, from a societal and  a healthcare perspective.
Methods/Design: A multi-centre cohort  study will be  performed, in which IVF singletons and IVF twin children 
born b e tw een  2003 and  2005 of w h o m  parents  received IVF t r e a tm e n t  in on e  of th e  five participating Dutch IVF 
centres, will be co m pared .  Data collection will focus on children at risk of health p rob lem s and  children in w h o m  
health p rob lem s actually occurred. First year of life da ta  will be  collected in approximately 1,278 children (619 
s ingletons and  659 twin children). Data up  to  th e  fifth year of life will be  collected in approximately 488 children 
(200 singletons and  288 twin children). O u tco m e  m easures  are health status, health-related quality o f  life and costs. 
Data will be ob ta ined  from hospital information systems, a paren t questionnaire  and existing registries.
Furthermore, a prognostic  m odel will be  d eve loped  th a t  reflects th e  short and  long-term costs and  health 
o u tco m e s  of IVF singleton and  twin children. This m odel will be linked to  a Markov m odel of th e  short-term  cost- 
effectiveness of single em bryo  transfer strategies versus d oub le  em bryo  transfer strategies to  enab le  th e  calculation 
of th e  long-term  cost-effectiveness.
Discussion: This is, to  our know ledge, th e  first s tudy th a t  investigates th e  long-term costs and health o u tc o m e s  of 
IVF singleton and  twin children and th e  long-term cost-effectiveness of single em bryo  transfer strategies versus 
d o u b le  em bryo  transfer strategies.
* Correspondence: mirjam.van.heesch@mumc.nl
d epartm ent of Clinical Epidemiology and Medical Technology Assessment,
Maastricht University Medical Centre, P.O. Box 5800, 6202 A Z  Maastricht, The 
Netherlands
Full list of author information is available at the end of the article
O © 2010 van  Heesch et al; licensee BioMed Central Ltd. This is an O pen A ccess article d istributed under the term s o f the Creative B io  Med Central C o m m o n s Attribution License (http://creativecom m ons.org/licenses/by/2.0), w hich  perm its unrestricted use, d istribution, and reproduction in any m edium , provided the origina l w ork is properly cited.
van Heesch et al. BMC Pediatrics 2010, 10:75
http://www.biomedcentral.com/1471-2431/10/75
Page 2 of 11
Background
In the Netherlands, about 16,000 IVF treatm ents are 
performed every year [1]. As a result, approximately 
2.3% of all Dutch children are born from a pregnancy 
established by in vitro fertilization (IVF) [2]. A common 
complication of IVF is multiple pregnancy [3], which 
occurs in 20-25% of all IVF pregnancies [4-7]. Obstetri­
cians and neonatologists express a preference to prevent 
twin pregnancies in IVF because of maternal and perina­
tal complications [7]. Pregnancy-induced maternal com­
plications occur three to seven times more often in 
multiple than in singletons pregnancies [8]. The most 
common maternal complications of a twin pregnancy 
are pregnancy-induced hypertension, pre-eclampsia, 
anaemia, antepartum  and postpartum  haemorrhage, 
uterine atony and dystocia, increased operative delivery, 
uterine rupture and preterm  labour [8,9]. It is well 
known that twin status is associated with perinatal com­
plications. Perinatal morbidity and mortality is increased 
four-to ten-fold in twins [8]. Twins are born prem a­
turely more often than singletons. Approximately 50% 
of twin deliveries occur before 37 weeks gestation 
[10-12], and this is considered to be the factor that is 
largely responsible for the excess of perinatal and neo­
natal deaths and neonatal morbidity in twins [11,13,14]. 
Twins also have a lower birth weight compared to sin­
gletons [9,15,16], even when born full term  [17]. 
Because of the high frequency of complications, the 
average twin pregnancy requires more medical care than 
a singleton pregnancy, resulting in higher costs. Results 
from the Dutch TW IN study indicated that hospital 
costs of children born from IVF up to one year follow­
ing birth add up to about €3,000 for singletons and 
€9,000 for twin children [18].
The explanation for the increased risk of a multiple 
pregnancy after IVF is the policy of transferring two 
embryos into the uterus (double embryo transfer; DET) 
[19], which is still customary in the majority of women 
receiving IVF treatment, particularly in older women. A 
successful way to reduce the number of twin pregnan­
cies after IVF is to transfer only one embryo (single 
embryo transfer; SET) [20-26]. The current policy in 
The N etherlands is to offer SET in good prognosis 
patients (i.e. young patients with good quality embryos). 
The decision for the number of embryos to transfer - 
either one or two embryos - is established by both the 
couple and professionals [27].
Several short-term  (cost-) effectiveness studies have 
shown that transferring one fresh embryo and then, if 
needed, one frozen-and-thawed embryo dramatically 
reduces the number of twin pregnancies while achieving 
similar cumulative pregnancy rates to transferring two 
embryos in good prognosis patients [20,21,23-26,28-30]. A
review by Fiddelers e t al. [31] of economic evaluations of 
SET versus DET concluded that, from a cost-effectiveness 
point of view, SET is only preferred in good prognosis 
patients and when frozen-and-thawed cycles are included. 
The conclusions of the review are confirmed by a detailed 
(cost-)effectiveness analysis [20,26] and a Markov cost- 
effectiveness model [32]. The Markov model compared 
seven embryo transfer strategies varying from three cycles 
SET to three cycles DET and several combination strate­
gies. From the Markov-chain based study, it was con­
cluded that DET is more effective but also more costly 
compared to SET, with an Incremental Cost-Effectiveness 
Ratio (ICER) around €20,000 for an extra live birth.
Interpretation of current cost-effectiveness studies 
comparing SET strategies with DET strategies is compli­
cated. First, live b irth  is frequently used as outcome mea­
sure. To reflect the fact that twin pregnancies and twin 
births carry a higher risk for complications than singleton 
pregnancies and singleton births, both singleton and twin 
births are counted as one unit of live birth. However, 
based on results of preference studies, counting a twin 
birth as one live birth is incorrect from a subfertile cou­
ples' point of view [33-39]. Furthermore, a live birth is an 
intermediate outcome as long-term consequences are not 
included. Besides, it is not a preference-based outcome 
measure as opposed to Quality Adjusted Life Years 
(QALYs), which is a commonly used outcome measure 
in economic evaluations. Second, published cost-effec­
tiveness analyses applied a limited time horizon, up to six 
months after delivery. If a child experiences permanent 
morbidity the consequences are lifelong, and thus data 
on long-term costs and outcomes associated with single­
tons and twins born after IVF should be included in the 
analysis in order to obtain a valid estimate of the incre­
mental cost-effectiveness of different embryo transfer 
strategies. Third, most parents prefer a complete family. 
This implies that cost-effectiveness studies should prefer­
ably include the first IVF treatment as well as subsequent 
attempts for a second child. Fourth, even with current 
data, a societal preference statem ent on the choice 
between SET and DET depends on the amount of money 
society is prepared to pay for one extra live birth (ceiling 
ratio) [31]. No agreement exists on an appropriate ceiling 
ratio for one extra live birth, as opposed to the ceiling 
ratio for a QALY [1,40]. The right to procreate is gener­
ally regarded as fundamental, and from this principle one 
would expect a high ceiling ratio.
The proposed study - the TwinSing study - will inves­
tigate the short (1-year) and long-term (5 and 18-year) 
costs, health outcomes and health-related quality of life 
(HRQoL) of twins and singletons born from IVF for 
broad use in cost-effectiveness analyses comparing SET 
strategies with DET strategies.
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Current evidence
Most studies on the long-term follow up of IVF children 
so far did n o t compare IVF twin children with IVF sin­
gletons, but compared children born from IVF with 
naturally conceived children [41-45].
Long-term health-related outcomes
Up till now only few studies have actually compared 
long-term health-related outcomes of IVF twins and IVF 
singletons [46-48]. They reported varying results regard­
ing physical health and developmental outcomes. Pin­
borg et al. [48] reported that twins between two and 
seven years of age have a similar risk of neurological 
sequelae and cerebral palsy compared to singletons of 
the same age. In another study, Pinborg et al. [47] 
observed no discrepancies between IVF twins and IVF 
singletons aged three to four years regarding severe neu­
rological disabilities, allergic disorders, common infec­
tions and motor function. Nevertheless, IVF twins had 
poorer speech development and poorer general health 
status. M ortality rates did not differ significantly 
between IVF twins and IVF singletons, although there 
was a tendency towards a higher mortality rate in IVF 
twins. Bonduelle et al. [46] reported that the occurrence 
of malformations was not statistically different between 
IVF twins and singletons, whereas the developmental 
outcomes of IVF twins, as measured with the Bayley 
instrument, were significantly worse compared to IVF 
singletons at the age of two years.
O ther studies compared both IVF singletons with 
naturally conceived singletons and IVF twins with natu­
rally conceived twins [42-45]. Although these studies 
provided figures about the long-term health status of 
IVF twins and IVF singletons, no statistics were pre­
sented and no conclusions were drawn regarding the 
comparison between IVF twins and IVF singletons. All 
three studies suggested that the health of IVF twins was 
worse than that of IVF singletons. Klemetti et al. [43] 
showed that the risks for cerebral palsy, behavioural dis­
orders, asthma, pneumonia and diarrhoea were higher 
for IVF twins aged two years compared with IVF single­
tons of the same age. Koivurova et al. [44] reported that 
six out of eight diseases were more prevalent in IVF 
twins than in IVF singletons, i.e. respiratory diseases, 
pneumonia, obstructive bronchitis, asthma, juvenile 
arthritis and neurological signs. Another study of Koi- 
vurova et al. [42] showed that risks of having diagnoses 
related to diseases affecting the central nervous system 
were higher for IVF twins. Furthermore, the proportion 
of children with low weight, low height and inability to 
perform at least one developmental test was higher in 
the IVF twin group compared to singletons for several 
age categories up to three years. StrOmberg et al. [45] 
found a higher proportion of neurological sequelae in 
IVF twins compared to IVF singletons aged 18 months
to 14 years. Overall, the results of these studies are 
ambivalent, some hinting at worse outcomes for IVF 
twins and some showing similar outcomes for IVF twins 
and singletons.
Long-term costs
At this moment only a few cost studies have been per­
formed [41-43,47,49]. Most studies were restricted to an 
evaluation of the use of hospital resources. Two studies 
statistically compared long-term resource use and/or 
costs of IVF twins and IVF singletons [47,49]. A study 
by Pinborg et al. [47] revealed no difference in the risk 
of hospitalization and the number of hospitalizations 
per child between IVF twins and IVF singletons aged 
three to four years. In contrast, they showed in another 
study that IVF twins aged two to seven years were 
more likely to be adm itted to a hospital, had more 
admissions per child, longer hospital stays, as well as 
more surgical interventions and special needs [49]. Even 
term  twins were more likely to be hospitalized than 
term singletons [49].
Other studies did not statistically confirm differences 
in resource use or costs of IVF twins and IVF singletons 
[41-43]. Koivurova et al. [42] concluded that the costs of 
post-neonatal care were almost equal for IVF twins and 
IVF singletons during a seven-year follow-up period. A 
large registry study by Ericson et al. [41] with an average 
follow-up of six years showed that IVF twins had about 
twice as much hospital days as IVF singletons. Klemetti 
et al. [43] also reported more resource use by IVF twins 
up to two to four years of age. Medication use was mea­
sured up to two years of age, whereas the use of hospital 
services was measured up to four years of age. More IVF 
twins than IVF singletons had long-term medication use, 
were hospitalised, and had longer hospital stays. Overall, 
the majority of these studies reported higher use of 
resources for IVF twins. It has been estimated that life­
time extra health care costs of a twin pregnancy add up 
to €30,000 in the Netherlands [50].
Long-term impact on parent's life
Mothers of two to five year old IVF twins experienced 
significantly higher levels of parenting stress and depres­
sion than mothers of IVF singletons and were less likely 
to obtain pleasure from their child and to be in paid 
employment [13,51].
Conclusion
Overall the current evidence confirms that post-neonatal 
costs are higher in IVF twins compared to IVF single­
tons. Reported results regarding health outcomes are 
inconclusive. Some studies were, however, not designed 
to detect significant differences between IVF twins and 
IVF singletons and probably lacked statistical power to 
detect differences. The available evidence is insufficient 
to estimate the long-term cost-effectiveness of SET stra­
tegies compared with DET strategies.
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Problem definition
In the Netherlands, long-term results from IVF children 
are currently lacking. It is timely to obtain an objective 
estimate of the long-term costs and health outcomes of 
twins and singletons born from IVF, to support the 
claim that twin pregnancies are a complication of IVF 
that should be prevented. Objective here means empiri­
cally based and taking account for sources of bias. To 
support the general believe that twin pregnancies are a 
complication of IVF and to make an evidence-based 
decision on the preferred embryo transfer strategy in 
IVF, both long-term costs and health outcomes of twins 
and singletons need to be estimated.
The TwinSing study is funded by the Netherlands 
Organisation for Health Research and Development 
(ZonMW), grant number 80-82310-98-09094. The study 
is approved by the Institutional Ethical Board of the 
Maastricht University Medical Centre (Ref no: 09-4-019) 
and the study is actively supported by the Dutch patient 
association Freya. The Ethical Board of the Maastricht 
University Medical Centre judged that the TwinSing 
study is not subject to the Medical Research Involving 
Human Subjects Act (WMO).
Objective and research questions
The objective of the TwinSing study is to investigate the 
short (1-year) and long-term  (5 and 18-year) costs, 
health outcomes and HRQoL of twins and singletons 
born from IVF. These results will be linked to a Markov 
model in which seven embryo transfer strategies are 
compared [32], to enable estimation of the long-term 
cost-effectiveness of SET strategies versus DET 
strategies.
The research questions are:
1. What are the short (1-year) and long-term (5 and 
18-year) health outcom es of IVF twins and 
singletons?
2. What are the short (1-year) and long-term (5 and 
18-year) costs of IVF twins and singletons?
3. W hat is the short (1-year) and long-term (5 and 
18-year) cost-effectiveness of SET strategies versus 
DET strategies from a societal and healthcare 
perspective?
4. W hat is the value of additional inform ation 
through research to reduce decision uncertainty?
Methods/Design
Design
A retrospective multi-centre (n = 5) cohort study will be 
performed, in which a representative sample of IVF twin 
children will be compared with a representative sample 
of IVF singletons with respect to mortality, health
outcomes, HRQoL and costs from birth up to five years 
of life. Subsequently, future costs and health outcomes 
up to 18 years of life will be modelled. Input for the 
model will be based on the empirically collected data up 
to five years of life, existing databases, literature and 
expert opinion.
Participants
The study population consists of twins and singletons 
born from IVF between 2003 and 2005, of whom par­
ents have received IVF treatment in one of the five par­
ticipating IVF centres in the Netherlands (Academic 
Medical Centre, Maastricht University Medical Centre, 
Radboud University Nijmegen Medical Centre, Erasmus 
Medical Centre and University Medical Center Utrecht). 
In the Netherlands, subfertility care is well-organized 
and centred in thirteen licensed clinics [52]. Hospitals 
without a licence can initiate and monitor the stimula­
tion phase and refer to a licensed hospital for both 
oocyte retrieval and embryo transfer (satellite clinics) or 
for embryo transfer alone (transport clinics). Five of the 
13 licensed centres and their collaborating transport- 
and satellite clinics, participate in the TwinSing study.
The fu l l  sa m p le  consists of all IVF twins and IVF sin­
gletons born between 2003 and 2005 of whom parents 
have received treatment in one of the participating cen­
tres. A total of 4,809 ongoing pregnancies were reported 
by these IVF centres between 2003 and 2005, of which - 
3,789 singleton and 1,020 twin pregnancies. The actual 
size of the full sample will be somewhat lower since the 
reported figures are indicative; they are based on 
ongoing pregnancies not live births. Inclusion of an 
older cohort of IVF children is not considered to be 
valid, since the quality and results of IVF, neonatal and 
paediatric care have improved considerably during the 
last decade and since this study relies heavily on retro­
spective data collection, both from existing registries as 
well as from parents.
Data collection will primarily focus on the subgroup of 
children 'at risk' for health problems and on those chil­
dren in which health problems have actually occurred. 
Therefore, for all children included in the full sample, 
information from the Perinatal Registry Netherlands 
(PRN) will be studied. Based on information from the 
PRN and the establishment of a clear set of criteria, all 
children at 'high risk' and a random sample of children 
at 'low risk' will be selected. All singleton children at 
'moderate risk' and a random sample of twin children at 
'm oderate risk' will also be selected (see figure 1). 
Together, these children will form the basis for empiri­
cal data collection with respect to the first year of life, 
and will further be referred to as the base sa m p le . Based 
on results up to the first year of life, the base sample of 
children will further be reduced for detailed data
van Heesch et al. BMC Pediatrics 2010, 10:75
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Figure 1 Risk stratification and sample size (figures are indicative).
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collection regarding the costs and health outcomes of 
the children up to five years of life and data estimation 
up to 18 years of life (further referred to as the reduced  
sam ple). Infant will be the unit of analysis. The selection 
of IVF twin children of a pair for inclusion in the base 
sample and reduced sample will occur independently.
In order to sufficiently take account of heterogeneity 
within the children who experienced health problems, it 
is expected that costs and outcome data of at least 100 
singletons and 100 twin children with health problems 
are required in the reduced sample. Regarding children 
without health problems, data of 50 singletons and 50 
twin children is expected to be sufficient, as variance 
will be considerably lower. Taking sufficiently account 
of missing data in all phases of data collection (5% for 
risk stratification, 10% for data collection up to one year 
of life and 20% for data collection up to five years of 
life), a sample size of 175 twin children with health pro­
blems, 56 twin children without health problems, 104 
singletons with health problems, and 56 singletons with­
out health problems, is required for the reduced sample.
Data collection
Data collection full sample
The five participating IVF centres will each provide a 
dataset consisting of mothers who have had an effective 
IVF treatm ent and gave birth to a singleton or twin 
between 2003 and 2005. The data received from the IVF 
centres will be linked to the PRN database, which 
encompasses information regarding mother, pregnancy 
and newborn. The data will be matched to the PRN 
database based on the birth date of the mother, parity 
of the mother, (an estimation of) the birth date of the 
child(ren), and whether it was a singleton or twin birth. 
Risk stratification
Risk stratification will be applied to all children in the 
full sample. Based on information from the PRN regard­
ing the pregnancy (weeks gestation) and the newborn 
(birth weight, Apgar score and congenital malforma­
tions), the children of the full sample will be assigned to 
a risk profile (i.e. 'low risk', 'm oderate risk' or 'high 
risk'). The risk stratification criteria are: 1) prematurity 
(< 37 weeks gestation); 2) 5-minute Apgar score (< 7); 
3) congenital malformations; and 4) b irth  weight 
(< 2,000 gram) (see figure 1). The criteria are set such 
that the probability of a false negative, i.e. the chance 
that a child 'at risk' is assigned to the low risk category, 
is minimized. A child will be assigned to the 'moderate 
risk' category if the child is born before 37 weeks gesta­
tion, has a Apgar score below seven, or has a congenital 
malformation. If the child also has a birth weight below 
2,000 gram, the child will be assigned to the 'high risk' 
category. The other children will be assigned to the 'low 
risk' category. Based on figures reported by the PRN
[12] and expert opinion it is expected that approxi­
mately 8% of the singletons will be assigned to the 
'moderate risk' or 'high risk' category. All 'moderate risk' 
and 'high risk' singletons and a random selection of 10% 
of the remaining ('low risk') singletons will be included 
in the base sample. Based on figures reported by the 
PRN [12] and expert opinion it is expected that half of 
the twin children is born before 37 weeks gestation, 
have a low APGAR score or a congenital malformation. 
Approximately 40% of these twin children will also have 
a low birth weight (20% of all twin children) and will be 
assigned to the 'high risk' category. The other 60% of 
these twin children will have a birth weight above 2000 
gram (30% of all twin children) and will be assigned to 
the 'm oderate risk' category [12]. All other children 
(50% of all twin children) will be assigned to the 'low 
risk' category. All twin children of the 'high risk' cate­
gory, a random selection of 30% of the 'moderate risk' 
category and a random selection of 10% of the 'low risk' 
category will be included in the base sample.
Empirical data collection up to the first year of life 
Data with respect to the first year of life will be col­
lected in children of the base sample. Based on figures 
reported by the PRN over 2004 [12] and expert opinion 
it is expected that approximately 1,278 children will be 
included in the base sample. The estimated number of 
children in each risk category is shown in figure 1.
Cost and outcome data up to the first year of life will 
be obtained from the hospital information systems of 
the relevant hospitals, existing registries and, if neces­
sary, patient charts will be reviewed to obtain relevant 
cost and outcome data. The following registries will be 
used: 1) the PRN, which encompasses inform ation 
regarding mother, pregnancy and the newborn; 2) the 
National Medical Registration (LMR), which registers 
medical and administrative data of all patients who have 
been admitted or have received outpatient treatment in 
Dutch hospitals; and 3) the Netherlands Twin registry 
(NTR), which follows a cohort 72,000 twins regarding 
pre- and perinatal information, health status, growth 
and motor development and behaviour [53,54]. As we 
intend to collect follow up data directly from hospital 
records, the use of data from the LMR will be optional. 
It is expected that data collection up to the first year of 
life will succeed in 90% of these children.
Empirical data collection from the first year of life up to the 
fifth year of life
Based on empirical collected costs and outcome data up 
to the first year of life, a subgroup of children will be 
selected for data collection up to the fifth year of life, 
referred to as the reduced sample. All children with 
resolved or persistent health problems, and a random 
sample of children without resolved or persistent health 
problem s will be included in the reduced sample.
van Heesch et al. BMC Pediatrics 2010, 10:75
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Assuming that missing data are completely at random, 
resolved and persistent health problems are expected in 
4.0% of the singletons and in 12.5% of the twin children. 
Approximately 488 children will be included in the 
reduced sample (see figure 1). Besides the data sources 
mentioned above, cost and outcome data up to the fifth 
year of life will also be gathered by means of a parent 
questionnaire. The questionnaire will consist of three 
parts, the first part referring to the past, the second part 
referring to the present and the third part referring to 
expectations regarding the future. The parent question­
naire will focus on health outcomes, HRQoL and costs. 
Data estimation up to the 18th year of life 
Costs and outcome data of the reduced sample up to 
the 18th year of life will be estimated, based on 1) 
empirical costs and outcomes up to five years of life; 2) 
parent estimations by means of a questionnaire; and 4) 
a matched sample (n = 250) of 18-year old twin chil­
dren, of whom NTR data referring to the past will be 
studied. The sample from the NTR will be chosen such 
that their past health at five years of age matches with 
the health status of the children of the reduced sample 
who will have an average age of five years. If empirical 
data are missing, data will be obtained by means of lit­
erature and/or expert opinion. Based on these data 
inputs, a prognostic model - the TwinSing model - will 
be developed.
Outcome measures
Outcome measures are:
1. Health outcomes of the singleton and twin chil­
dren, such as (perinatal) mortality, morbidity, perina­
tal outcomes (birth weight, prematurity, APGAR), 
malformations, developmental problems (psychomo­
tor, cognitive and growth) and behavioural 
outcomes.
2. Health related quality of life of the singleton and 
twin children. HRQoL will be measured via proxy 
ratings by (one of) the parents by means of the 
EuroQol (EQ-5D) and the Health Utilities Index 
(HUI3). The EuroQol provides a simple descriptive 
profile, combining scores on mobility, self-care, daily 
activities, pain/discomfort and depression/anxiety 
into a single index value for health status and a VAS 
scale (0-100). Utility scores for the health states will 
be calculated by using the UK-tariff [55] and by 
using the Dutch EQ-5D tariff [56]. The reliability 
and validity of the EQ-5D has been established [57]. 
The proxy version of the EQ-5D has good construct 
validity and convergent validity [58]. The HUI3 will 
also be used as some studies have reported problems 
regarding speech development and cognitive pro­
blems. The HUI3 is a generic measure consisting of
eight attributes (vision, hearing, speech, ambulation, 
dexterity, emotion, cognition and pain). Each attri­
bute has five or six levels and 972,000 possible 
health states can be defined. The HUI3 has a multi­
plicative scoring function which was derived from 
the Standard Gamble (SG) and Visual Analogue 
Scale (VAS) in a random sample of the Canadian 
general population, resulting in possible utility scores 
ranging from -0.36 to 1.00 [59].
3. (Societal) costs, including resources consumed 
within the health care sector, such as NICU admis­
sions, hospital admissions, diagnostics, treatments, 
surgical interventions, and special needs (e.g. phy­
siotherapy, occupational therapy or speech therapy); 
resources consumed outside the health care sector, 
such as support, special education, school absence 
and institutional care; patient and family costs, such 
as out-of-pocket expenses, travel costs and time 
costs; and productivity costs.
Data analysis 
Empirical data
Health outcomes of the singleton and twin children, 
including mortality, perinatal outcomes, morbidity and 
developmental and behavioural problems will be ana­
lysed. Subsequently, health outcomes will be expressed 
in QALYs. QALYs will be calculated based on mortality 
and HRQoL data retrieved from both the EQ-5D and 
the HUI. Costs will be calculated by multiplying 
volumes of resource use with the cost price. Cost prices 
will be obtained from the Dutch manual of costing stu­
dies [60] and financial departments of the participating 
centres. For cost prices that are not readily available, 
such as institutional care, special education and school 
absence, cost price calculations will be performed.
Descriptive statistics will be used to describe the main 
characteristics and outcomes of IVF singleton and twin 
children. The base sample and the reduced sample are 
not representative of the Dutch IVF population as a 
consequence of the risk stratification and the random 
selection of subsamples of healthy children. Therefore, 
before analysing the data, the proportions of high, mod­
erate and low risk singletons and twin children will be 
adjusted, to properly reflect the ratios in the original 
population.
Results will be presented with and without stratifica­
tion for maternal age and parity. The issue of selection 
(information) bias will be investigated explicitly by com­
paring PRN data of children with (completely) missing 
data with PRN data of children included in the analysis. 
Development TwinSing model
A prognostic model will be developed which estimates 
the short and long-term costs and health outcomes of
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IVF singletons and IVF twin children. The structure and 
modelling method of the TwinSing model will be deter­
mined in close cooperation with experts in the project 
team and the participating centres. We expect that a 
Markov model will best suit the data; however, the final 
decision regarding which modelling method to use will 
be made after data become available.
Short and long-term cost-effectiveness of SET strategies 
versus DET strategies
The TwinSing model will be linked to a short-term  
M arkov model developed at the University Hospital 
Maastricht [32], that compared seven embryo transfer 
strategies varying from three cycles SET to three cycles 
DET and several com bination strategies. Parameter 
values were based on data from a large randomised con­
trolled trial in which patients who started their first IVF 
cycle in the Maastricht University Medical Centre were 
included.
The economic evaluation will be performed from both 
the societal and the health care perspective and the time 
horizon will be 18 years. Cost and benefits occurring 
after one year will be discounted according to national 
guidelines [61].
The ultimate model - in which the short-term Markov 
model and the TwinSing model have been integrated - 
will enable the estimation of the cost-effectiveness of 
SET strategies versus DET strategies, expressed as the 
additional costs per life year gained and the additional 
costs per QALY. The cost-effectiveness will be analysed 
using a short term time frame (1-year) and a long term 
time frame (5 and 18-year).
Uncertainty in the model will be investigated by one-way 
sensitivity analysis and probabilistic sensitivity analysis. 
One-way sensitivity analysis will be used to test the 
robustness of the results for (methodological) uncertainties 
(e.g. discount rate and health-related quality of life instru­
ment used). Parameter uncertainty will be further tested 
using probabilistic sensitivity analysis. Distributions will be 
fitted for all parameters in the model, except fixed para­
meters. Beta distributions will be fitted for probabilities 
and gamma distributions will be fitted for costs. Net 
monetary benefits (NMB) will be calculated for each strat­
egy and cost-effectiveness acceptability curves (CEACs) 
will be constructed. CEACs provide a graphical represen­
tation of the probability that a strategy is cost-effective for 
a range of ceiling ratios. Subsequently, the cost-effective­
ness acceptability frontier (CEAF) will be established, to 
indicate the preferred strategy.
As most parents prefer a complete family instead of 
one child, a secondary analysis will be perform ed in 
which the cumulative pregnancy rates and live birth 
rates of subsequent IVF treatments (up to three) will be 
estimated. Doing so, the costs and outcomes of children 
of the second or third IVF treatment will be evaluated
to estimate the cost-effectiveness of SET strategies ver­
sus DET strategies.
Value of information analysis
Inherent to modelling is that results are surrounded by 
an amount of uncertainty. Value of information analysis 
addresses the issue whether the most efficient embryo 
transfer strategy can be adopted based on the available 
knowledge after finishing this study or whether more 
evidence is required [62-65]. An expected value of per­
fect inform ation (EVPI) analysis will be performed, 
which draws on the probabilistic model developed in 
this study. Subsequently partial EVPIs will be calculated 
to identify the parameters for which more accurate esti­
mates are the most valuable and which should be the 
focus of future research.
Ethical considerations
The study protocol has been reviewed and approved by 
the Medical Ethical Committee of the Maastricht Uni­
versity Medical Centre (MUMC). Parents will be 
informed in written format about the TwinSing study 
and are asked to return a signed informed consent form 
if they decide to participate in the parent questionnaire.
Funding
A grant was obtained from the efficiency research pro­
gramme, round 2009, of the Netherlands Organization 
for Health and Development (ZonMW).
Discussion
Multiple pregnancies are regarded as a complication of 
IVF. To date, SET is more and more accepted as the solu­
tion for the high frequency of twin pregnancies after IVF. 
To support the claim that twin pregnancies are a compli­
cation of IVF, the long-term costs and outcomes of twins 
and singletons should be determined. To our knowledge 
this is the first study on both long-term (societal) costs 
and health outcomes of IVF twins and singletons, allowing 
us to calculate the long-term cost-effectiveness of several 
(combinations of) SET and/or DET strategies.
This study will use QALYs as outcom e measure, 
which will enhance comparison with other health care 
programs and the interpretation of the ICERs. Further­
more, this study will be conducted from the societal 
perspective and this includes not only hospital costs, but 
also productivity, patient and family costs. M ost pre­
vious studies focused on hospital costs only, neglecting 
costs outside the healthcare sector. Analyses will also be 
performed from the healthcare perspective.
Another strength of this study protocol is its efficient 
design. The larger part of the health problems and asso­
ciated costs will occur in a relatively small group of chil­
dren. The study is set up such that data collection 
focuses on these children. Data collection regarding the
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first year of life is focused on children at high risk of 
health problem s due to a prem aturity, a low Apgar 
score, a congenital malformation or a low birth weight. 
Data collection regarding the second to fifth year of life 
is focused on children who experienced health problems 
during their first life year. Additional advantage is that, 
due to the decreasing number of participants making up 
the sample size in later stages of the study, a particularly 
high level of detail can be reached in the data collection.
Although this study will apply the commonly used 
QALY as measure of outcome, a number of potential 
problem s are to be expected. The first question is 
whether the QALY concept is suitable to value QALYs 
'g en era ted ' or 'crea ted ', instead of QALYs g a in e d , for 
which the QALY framework was originally developed. 
Furthermore, a twin consists of two live-born children. 
An interesting issue in using QALYs as outcome mea­
sure is that a healthy twin will theoretically generate 
twice as much QALYs as a healthy singleton, which is 
the total opposite compared to how twins have been 
valued in cost-effectiveness analyses thus far. As twins 
are more common among woman receiving DET, 
including the QALYs of both twin children in the cost- 
effectiveness analysis will have considerable impact on 
the ICERs [32]. Furthermore, it can be expected that 
parents with a single child after SET, will more often 
undergo subsequent IVF treatment(s) than parents with 
a twin after DET. As a result, the long-term cost-effec­
tiveness analysis including only the first IVF treatment 
is of limited value. It does not reflect the real world 
situation in which parents can opt for up to three IVF 
treatments. Our secondary analysis including subsequent 
IVF treatments will take account of this imbalance.
Moreover, when using QALYs, an interesting question 
is furthermore whether the QALYs of parents and sib­
lings should be taken into account as well. For example, 
the birth of a (handicapped) child may have a consider­
able impact on family members. It should be considered, 
if and how QALYs of the parent and family members 
should be included in the analysis.
Conclusion
This study will provide information on the short and 
long-term incremental (societal costs) and health out­
comes of IVF twin children compared with IVF single­
tons. Subsequently, it will provide further evidence 
regarding whether SET strategies are more efficient than 
DET strategies. Results of this study will be of interest 
for patients, clinicians, health care policymakers and 
insurers, both nationally and internationally.
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